Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Salix Licensing Alfa Wassermann Drug

By Drug Discovery Trends Editor | August 10, 2012

RALEIGH, N.C. (AP) – Salix Pharmaceuticals said it has agreed to pay $10 million, plus additional payments to license an experimental extended release drug for intestinal and respiratory diseases, including Crohn’s disease.

The formulation of rifaximin from Alfa Wassermann S.p.A is designed to pass through the stomach before being released into the intestinal tract. In addition to the upfront payment, Salix has agreed to pay a $25 million development milestone if the drug is approved for Crohn’s disease. Salix will pay additional fees based on sales and royalties of the drug.

Alfa Wassermann, based in the Netherlands, will manufacture rifaximin for Salix. The drug is currently used to treat diarrhea caused by certain types of bacteria.

Separately, Salix reported better-than-expected adjusted earnings for the second quarter and raised its full-year guidance. Sales of its top-seller, Xifaxan for traveler’s diarrhea and neurological problems associated with liver failure, rose 34% during the quarter.

Date: August 8, 2012
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50